This is Part 3 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. 

 

In this video, Drs. Krishnansu Tewari, Noelle Cloven, and Alyssa Bujnak discuss the management of advanced uterine papillary serous carcinoma with mismatch repair proficiency (MMRp). The patient is a 72-year-old woman presenting with postmenopausal vaginal bleeding, abdominal discomfort, and cul-de-sac nodularity. She is ultimately diagnosed with FIGO stage IVB uterine papillary serous carcinoma that is MMRp and p53-positive, with upper abdominal metastases confirmed at surgical exploration.

 

The faculty explore the rationale for primary debulking surgery vs neoadjuvant chemotherapy in patients with advanced uterine serous carcinoma, and how comprehensive biomarker testing—including MMR status, p53, POLE, and HER2—can further stratify prognosis and guide treatment within the MMRp population. They also discuss the emerging role of circulating tumor cell-free DNA as a monitoring tool in endometrial cancer and highlight novel clinical trials that may offer additional options for this high-risk patient population.